The Rady Children’s Institute for Genomic Medicine announced a collaboration with PlumCare RWE to expand its rWGS-based newborn screening program in Greece. PlumCare and the Greek National Public Health Organization plan to recruit at least 1,000 families for the pilot program
The FDA has approved medicine for Amyotrophic Lateral Sclerosis(ALS) developed by Amylyx Pharmaceuticals. This brings ALS patients to two drugs, along with riluzole, which was approved 25 years ago. Like the conventional drug, Amylyx's drug cannot cure ALS, but clinical trials have shown it to slow the progression of ALS symptoms and prolong survival.
AstraZeneca will acquire gene-editing company LogicBio for $68 million. AstraZeneca will buy all of LogicBio's outstanding shares, and the value of the shares is over 600% compared to the time before the acquisition announcement. LogicBio has the technology to edit genes with homologous recombination technology, not CRISPR-based technology.
AstraZeneca가 유전자 편집 기업 LogicBio를 6천8백만 달러에 인수할 예정입니다. AstraZeneca가 LogicBio의 모든 발행주식을 인수하는 방식으로 진행되며, 주식 가치는 인수 발표전 시점과 비교해 600% 이상의 가치로 평가되었습니다. LogicBio는 CRISPR 기반 기술이 아닌, homologous recombination 기술로 유전자를 편집하는 기술을 보유하고 있습니다. Original Article: BioPharma Dive.AstraZeneca to acquire gene editing biotech LogicBio
Do you want to keep up with the latest post of this series?